<DOC>
	<DOC>NCT00795873</DOC>
	<brief_summary>Post approval study measuring safety outcomes on the Ovatio CRT-D and SITUS OTW LV lead over 5 years.</brief_summary>
	<brief_title>OVATIO CRT and SITUS OTW LV Lead Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>NYHA Class III/IV Stable medical regimen QRS greater than or equal to 130 ms LVEF less than or equal to 35% VT of transient or reversible causes Incessant VT Currently implanted with a lead positioned through the coronary sinus (unless it is the SITUS OTW LV lead) Cardiac revascularization or angioplasty within the last month Heart failure due to correctable valve disease Chronic, medially refractory AT Enrolled in another clinical study that may confound the results of this study Life expectancy less than 6 months Inability to understand the purpose of the study or refusal to cooperate Inability or refusal to provide informed consent Unavailable for scheduled followup with the implanting practice Sensitivity to 1 mg dexamethasone sodium phosphate Less than 18 years of age Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>cardiac resynchronization therapy</keyword>
</DOC>